Adenomyosis: Genomic Mechanisms and Biological Response

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03428854

Enrollment

Registered

2018-02-12

Start date

2020-12-01

Completion date

2022-10-01

Last updated

2021-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyosis, Abnormal Uterine Bleeding

Brief summary

Examination of genomic and biologic responses to LNG-IUS in patients with adenomyosis.

Detailed description

Examination of genomic and biologic responses to LNG-IUS in patients with adenomyosis.

Interventions

DRUGLNG-IUS

Levnorgestrel containing IUD

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 60 Years

Inclusion criteria

* Abnormal bleeding in the presence of Adenomyosis as demonstrated by MRI

Exclusion criteria

* Other causes of abnormal bleeding such as fibroids, endometrial polyps, malignancy * Presence of endometriosis

Design outcomes

Primary

Measure	Time frame	Description
Menstrual blood loss	12 months	Pictorial blood loss assessment chart

Secondary

Measure	Time frame	Description
Quality of Life	12 months	SF-12
Pain	12 months	Visual analog scale

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026